Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
39.39
USD
|
+5.38%
|
|
+2.82%
|
+37.34%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,628
|
1,855
|
2,115
|
4,720
|
6,167
|
-
|
-
|
Enterprise Value (EV)
1 |
2,628
|
1,278
|
1,470
|
2,867
|
4,794
|
5,322
|
5,913
|
P/E ratio
|
-19.7
x
|
-9.79
x
|
-7.73
x
|
-7.43
x
|
-11.9
x
|
-10.6
x
|
-10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
61.1
x
|
63.1
x
|
59.8
x
|
408
x
|
2,821
x
|
2,312
x
|
254
x
|
EV / Revenue
|
61.1
x
|
43.5
x
|
41.6
x
|
248
x
|
2,193
x
|
1,995
x
|
244
x
|
EV / EBITDA
|
-24.3
x
|
-6.91
x
|
-5.81
x
|
-5.96
x
|
-8.15
x
|
-8.24
x
|
-8.57
x
|
EV / FCF
|
-25.5
x
|
-8.31
x
|
-6.25
x
|
-8
x
|
-10.8
x
|
-11
x
|
-12
x
|
FCF Yield
|
-3.92%
|
-12%
|
-16%
|
-12.5%
|
-9.26%
|
-9.13%
|
-8.33%
|
Price to Book
|
4.58
x
|
3.1
x
|
3.14
x
|
1.78
x
|
4.48
x
|
6.17
x
|
12
x
|
Nbr of stocks (in thousands)
|
66,380
|
73,687
|
88,791
|
164,565
|
164,986
|
-
|
-
|
Reference price
2 |
39.59
|
25.17
|
23.82
|
28.68
|
37.38
|
37.38
|
37.38
|
Announcement Date
|
3/2/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
50.04
|
42.98
|
29.39
|
35.38
|
11.58
|
2.186
|
2.668
|
24.24
|
EBITDA
1 |
-
|
-108.1
|
-184.9
|
-253.2
|
-481.1
|
-588
|
-645.4
|
-689.9
|
EBIT
1 |
-54.12
|
-110.7
|
-188
|
-258.3
|
-487.2
|
-590.3
|
-642.4
|
-663.6
|
Operating Margin
|
-108.15%
|
-257.54%
|
-639.7%
|
-730.01%
|
-4,207.12%
|
-26,996.18%
|
-24,079.59%
|
-2,737.55%
|
Earnings before Tax (EBT)
1 |
-52.04
|
-108.5
|
-187.1
|
-249.1
|
-439.9
|
-511.5
|
-592.2
|
-624.3
|
Net income
1 |
-61.9
|
-110.4
|
-187.1
|
-248.7
|
-436.4
|
-511.5
|
-587.6
|
-630.7
|
Net margin
|
-123.7%
|
-256.8%
|
-636.58%
|
-702.95%
|
-3,768.28%
|
-23,395.68%
|
-22,025.63%
|
-2,601.56%
|
EPS
2 |
-1.049
|
-2.010
|
-2.570
|
-3.080
|
-3.860
|
-3.132
|
-3.542
|
-3.657
|
Free Cash Flow
1 |
-52.2
|
-103
|
-153.7
|
-235.2
|
-358.3
|
-444
|
-485.8
|
-492.8
|
FCF margin
|
-104.32%
|
-239.62%
|
-522.99%
|
-664.83%
|
-3,094.14%
|
-20,306.43%
|
-18,208.91%
|
-2,032.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/2/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
9.46
|
7.578
|
9.116
|
3.356
|
15.33
|
7.014
|
3.824
|
-
|
0.742
|
-
|
0.4091
|
0.4091
|
0.4091
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-178.4
|
-
|
-146.1
|
-154
|
-161.6
|
-169.6
|
-171
|
EBIT
1 |
-52.91
|
-57.95
|
-62.09
|
-76.53
|
-61.71
|
-75.16
|
-108.8
|
-123.2
|
-180
|
-140.9
|
-144.3
|
-151.3
|
-155.2
|
-163.7
|
-166.7
|
Operating Margin
|
-559.33%
|
-764.7%
|
-681.1%
|
-2,280.48%
|
-402.52%
|
-1,071.53%
|
-2,845.11%
|
-
|
-24,256.47%
|
-
|
-35,276.29%
|
-36,987.85%
|
-37,948.9%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-52.68
|
-57.65
|
-61.22
|
-73.63
|
-56.63
|
-68.1
|
-98.3
|
-112.3
|
-161.2
|
-116
|
-124.6
|
-132.1
|
-136.7
|
-147.5
|
-151.7
|
Net income
1 |
-52.68
|
-57.65
|
-61.22
|
-73.33
|
-56.51
|
-68.1
|
-98.3
|
-108.4
|
-161.5
|
-116
|
-125.2
|
-132.1
|
-136.5
|
-146.8
|
-151.3
|
Net margin
|
-556.83%
|
-760.72%
|
-671.58%
|
-2,185.01%
|
-368.6%
|
-970.89%
|
-2,570.55%
|
-
|
-21,770.49%
|
-
|
-30,611.83%
|
-32,280.32%
|
-33,367.12%
|
-
|
-
|
EPS
2 |
-0.7100
|
-0.7800
|
-0.8200
|
-0.8700
|
-0.6300
|
-0.7200
|
-0.9200
|
-0.9900
|
-1.140
|
-0.7000
|
-0.7591
|
-0.7987
|
-0.8216
|
-0.8748
|
-0.9028
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/9/22
|
11/7/22
|
2/27/23
|
5/8/23
|
8/8/23
|
11/6/23
|
2/26/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
123
|
-
|
577
|
645
|
1,853
|
1,373
|
846
|
255
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-52.2
|
-103
|
-154
|
-235
|
-358
|
-444
|
-486
|
-493
|
ROE (net income / shareholders' equity)
|
-
|
-68.5%
|
-34.7%
|
-38.6%
|
-34.8%
|
-30.8%
|
-50.2%
|
-100%
|
ROA (Net income/ Total Assets)
|
-31.7%
|
-28%
|
-28.7%
|
-32.1%
|
-30.4%
|
-28%
|
-36.4%
|
-52.8%
|
Assets
1 |
195.6
|
394
|
652.7
|
774.5
|
1,436
|
1,827
|
1,614
|
1,193
|
Book Value Per Share
2 |
-2.590
|
8.650
|
8.130
|
7.580
|
16.10
|
8.340
|
6.060
|
3.130
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-3.100
|
-
|
7.320
|
-
|
Capex
1 |
2.59
|
2.93
|
6.53
|
10.8
|
7.73
|
9.39
|
11.3
|
12.5
|
Capex / Sales
|
5.17%
|
6.82%
|
22.21%
|
30.57%
|
66.74%
|
429.57%
|
424.73%
|
51.7%
|
Announcement Date
|
3/30/20
|
3/2/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Last Close Price
37.38
USD Average target price
44.82
USD Spread / Average Target +19.90% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.33% | 6.17B | | +29.03% | 49.18B | | -0.10% | 42.11B | | +47.13% | 40.37B | | -5.26% | 28.85B | | +11.48% | 26.09B | | -22.74% | 18.71B | | +9.06% | 13.26B | | +30.01% | 12.32B | | -1.51% | 11.99B |
Other Biotechnology & Medical Research
|